Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Sales (2017 - 2025)

Protagonist Therapeutics' Return on Sales history spans 9 years, with the latest figure at 6.03% for Q4 2025.

  • For Q4 2025, Return on Sales fell 683.0% year-over-year to 6.03%; the TTM value through Dec 2025 reached 2.84%, down 348.0%, while the annual FY2025 figure was 2.84%, 347.0% down from the prior year.
  • Return on Sales for Q4 2025 was 6.03% at Protagonist Therapeutics, up from 8.35% in the prior quarter.
  • Across five years, Return on Sales topped out at 10.32% in Q4 2021 and bottomed at 47.68% in Q2 2022.
  • The 5-year median for Return on Sales is 1.24% (2023), against an average of 4.7%.
  • The largest YoY upside for Return on Sales was 42124bps in 2021 against a maximum downside of -10654bps in 2021.
  • A 5-year view of Return on Sales shows it stood at 10.32% in 2021, then crashed by -103bps to 0.3% in 2022, then soared by 1069bps to 2.95% in 2023, then plummeted by -73bps to 0.8% in 2024, then crashed by -856bps to 6.03% in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Return on Sales are 6.03% (Q4 2025), 8.35% (Q3 2025), and 6.27% (Q2 2025).